الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
HCV plays a major role as a cause of chronic liver injury, with potential for neoplastic degeneration.
Hepatocellular carcinoma (HCC) is an increasingly prevalent clinical problem worldwide.
Mannose-binding lectin 2 (MBL2) plays an important role in the innate immune system, acting as an opsonin factor by activation of antibody-independent pathway of the complement system. Impaired production of MBL2 may therefore cause insufficient complement activation, thus facilitating disease susceptibility and progression and a significantly increased risk for the development of severe infections
The aim of this study was to assess blood level of mannose-binding lectin-2 gene polymorphism to detect the association between gene polymorphism with development of hepatitis C induced HCC, Moreover an evaluation of both serum levels of alpha feto protein and CD25 as markers for HCC was detected and whether they correlate with (MBL2) gene polymorphism and tumer stage of HCC.
This study included 88 patients (66 male and 22 female) their ages ranged between (30-65years) in addition to 30 apparently healthy subjects age and gender matched as control group (18 male and 12 female) with age ranged between (38-50years). The studied subjects were divided into three groups: group 1:
It included 58 patients with HCC and +ve for HCV (46 males and 12 females). Their ages were ranged between (30-65 years) and their mean age was (49.43±8.80 years).
group 2:
It included 30 patients with HCV without HCC (20 males and 10 females). Their ages were ranged between (32-61 years) and their mean age was (48.73±7.80 years). group 3:
It included 30 apparently healthy subjects as acontrol group (18 males and 12 females). Their ages were ranged between (38-50 years) and their mean age was (43.93±4.48 years).
The results of this study revealed that:
- Non significant difference between the three studied groups as regard age and gender.
-Non significant difference between HCC cases and HCV cases as regard (ALT, AST, Direct bilirubin, Total bilirubin, GGT and alkaline phosphatase) while there is significant difference between the two group as regard total protein and albumin which is lower among HCC group.
-Significant difference between HCC cases and control as regard (ALT, AST, total protein, Albumin, Direct bilirubin, Total bilirubin, GGT and alkaline phosphatase).
-Significant statistical difference between HCV cases and control as regard (AST, ALT, total protein, Albumin, Direct bilirubin, Total bilirubin, GGT and alkaline phosphatase).
-Higher AFP in HCC group than HCV and control group. Also there is higher AFP in HCV group than control.
- Higher CD25 in HCC group than HCV and control group and higher CD25 in HCV group than control.
-Significantly higher viral load in HCC group than in HCV group.
-GC genotype was significantly of higher rate among HCC cases than control with odds ratio (18) and 95% CI (4.73 – 68.53), also GG/GC genotype was significantly more frequent in HCC cases than control with odds ratio (10.5) and 95% CI (3.62 – 30.43), On comparing alleles, G allele was of higher rate among HCC cases than control with odds ratio (4) and 95% CI (1.80 – 8.89).
-Both MBL2 genotypes distribution were non significantly different in HCV cases and control, On comparing alleles, there was non significant difference regarding alleles in HCV cases and control.
-That GC genotype was significantly of higher rate among HCC cases than HCV cases with odds ratio 8.25 and 95% CI (2.81 – 24.24), also GG/GC genotype was significantly more frequent in HCC cases than HCV cases with odds ratio 7.22 and 95% CI (2.67 – 19.49).On comparing alleles, G allele was of higher rate among HCC cases than HCV cases with odds ratio 3.53 and 95% CI (1.63 – 7.65).
-Non significant statistical difference between GG/GC and CC MBL2 genotypes as regard number and site of tumor.
-Non significant difference between GG/GC versus CC genotype in both HCC and HCV groups regarding ALT, total protein, direct bilirubin, total bilirubin, GGT and alkaline phosphatase while regarding alpha feto protein it was significantly higher among GG/GC than CC genotype patients in both groups but CD25 is significantly higher among GG/GC than CC genotype patients in HCC group only.
-A significant positive correlation between CD25 and ALT, AST, total bilirubin, direct bilirubin, GGT and ALP with a significant negative correlation between CD25 and total protein and albumin in HCC group. Also, there is a significant positive correlation between CD25 and albumin in HCV group. And a significant negative correlation between CD25 and AFP in control group.
-A significant positive correlation between AFP and total protein, albumin, direct bilirubin, GGT, and ALP in HCC group. Also, there is a significant positive correlation between AFP and AST, total protein, total bilirubin and direct bilirubin in HCV group. And a significant positive correlation between AFP and total bilirubin in control group.
-The validity of CD25 for prediction of HCC cases from HCV cases with area under the curve 0.96 for CD25 and 0.93 for AFP. At Cut off point 5830 pg/ml for CD25 its Sensitivity is 84.5% , Specificity is 96.7%, negative predictive value 76.3%, positive predictive value 98% and Accuracy 88.6%. While at Cut off point 12.7 ng/ml for AFP its Sensitivity is 82.8%, Specificity is 73.3%, negative predictive value 68.8%, positive predictive value 85.7% and Accuracy 79.5%.